Категории
Как цитировать
Аннотация
Cardio-vascular diseases (CVD) are considered as the main reason of mortality nowadays. One of its main provoking agents is hyperlipidemia and atherosclerotic injuries. HMG-CoA reductase inhibitors (Statins) are first line antihypercholesterolemic drugs and are widely used for management of cardiovascular diseases, though they have severe side effects. Revealing of these drugs side effects are dose-dependent. The literature sources show the possibility to reduce drug dose without reduction of therapeutic effect by combination of statins with natural polyphenols. All the parts of grape vine are rich with polyphenolic compounds, including leaves and shoots; It is especially important to derive natural polyphenols from Georgian grape vines, standardization and study of their influence on statins pharmacokinetics.
Библиографические ссылки
დაავადებათა კონტროლისა და საზოგადოებრივი ჯანმრთელობის ეროვნული ცენტრი – სტატისტიკური ცნობარი 2017;
კლინიკური პრაქტიკის ეროვნული რეკომენდაციების და დაავადებათა მართვის სახელმწიფო სტანდარტების შემუშავების, შეფასებისა და დანერგვის ეროვნული საბჭოს, გულსისხლძარღვთა დაავადებების (გსდ) რისკის შეფასება და მართვა, საქართველოს შრომის, ჯანმრთელობისა და სოციალური დაცვის მინისტრის 2014 წლის 8 მაისის № 01 - 105/ო ბრძანება.
Arca M., Pigna G., Favoccia C., Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis, Bentham Science Publishers 2012, pp. 684-686
Baur J.A, Sinclair D.A., Therapeutic potential of Res- veratrol: the in vivo evidence, Neture Reviews, Drug Discovery 2006, pp. 493-506
Campolongo G., Riccioni C.V., Raparelli V., Spoletini I., Marazzi G., Vitale C., Volterrani M., The combination of nutraceutical and simvastatin enhances the effect of simvastatin alone in normalising lipid profile without side effects in patients with ischemic heart disease, IJC Metabolic & Endocrine 11, 2016, pp. 3-6
Cardiovascular diseases (CVDs) 2017, available at: http: //www .who. int/ mediacentre/factsheets/fs317/en/
Egert S., Rimbach G., Which Sources of Flavonoids: Complex Diets or Dietary Supplements?, Advances in Nutrition, vol.2, 2011, pp. 8-14
Gliozzi M., Walker R., Muscoli S., Vitale C., Gratteri S., Carresi C., Musolino V., Russo V., Janda E., Ragusa S., Aloe A., Palma E., Muscoli C., Romeo F., Mollace V., Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia, Internation Journal of Cardiology 170, 2013, pp.140-145
Global Atlas on Cardiovascular Diseases Prevention and Control–2011,WHO, WHF, WSO;
Jellinger P., Handelsman Y., Rosenblit P., Bloomgar- den Z., Fonseca V., Grunberger G., Guerin C., Bell D., Mechanick J., Pessah-Pollack R., Wyne K., Smith D., Brinton E., Fazio S., Davidson M., American Association of Clinical Endocrinologists and American College of Endocrinology, Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease, Endocrine practice vol.23. 2017, pp. 479-497
Mega J., Stitziel N., Smith g., Chasman D., Caulfield M., Devlin J., Nordio F., Hyde C., Cannon Ch., Sacks F., Poulter N., Sever P., Ridker P., Braunwald E., Melander O., Kathiresan S., Sabatine M., Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials, Lancet 2015, 385, pp. 2264-2271
Ramasubbu K., Estep J., White D.L., Deswal A., Mann D.L., Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy, Journal of the American College of Cardiology Vol. 51, 2008, pp. 415-426
Shitara Y., Sugiyama Y., Pharmacokinetic and pharmacodynamics alteration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions, Pharmacology and Therapeutics Vol.112, 2006, pp. 71-105
Sung I.K, Sang K.N., Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect, Journal of Nutritional Biochemistry 18, 2007, pp. 179-183
Wang H., Pao L., Hsiong C., Shih T., Lee M., Hu O., Dietary Flavanoids Modulate CYP2C to Improve Drug Oral Bioavailability and Their Qualitative/Quantitative Structure – Activity Relationship, The AAPS Journal Vol 16, 2014, pp. 258-268
Yusuf S., Bosch J., Dagenais G., Zhu J., Xavier D., Liu L., Pais P., Lopez-Jaramillo P., Leiter L.A., Dans A., Avezum A., Piegas L.S., Parkhomenko A., Keltai K., Keltai M., Sliwa K., Peters R.J.G., Held C., Chazova I., Yusoff K., Lewis B.S., Jansky P., Khunti K., Toff W.D., Reid C.M., Varigos J., Sanchez-Vallejo G., McKelvie R., Pogue J., Jung H., Gao P., Diaz R., Lonn E., Cholesterol Lowering in Inter- mediate-Risk Persons without Cardiovascular Disease, New English Journal of Medicine 2016, pp. 2021-2031
Zhelyazkova-Savova M., Gancheva S., Sirakova V., Potential statin-drug interactions: prevalence and clinical sig- nificance, SpringerPlus 2014, pp. 1-8
საქართველოს სამკურნალო საშუალებათა რეესტრი - http://pharmacy.moh.gov.ge/Pages/Products.aspx